Mainz Biomed (MYNZ) investor reports 10.7% ownership stake in common shares
Rhea-AI Filing Summary
Kevin Michael Donahue filed a Schedule 13G reporting beneficial ownership of 643,850 shares of Mainz Biomed N.V. common stock, representing 10.7% of the outstanding class.
He reports sole power to vote and to direct the vote for all 643,850 shares, with no shared voting authority. He also reports sole power to dispose or direct the disposition of these shares, again with no shared dispositive power. The filing characterizes him as an individual U.S. investor, not part of a group and not holding the stake on behalf of another person or subsidiary.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in MYNZ does Kevin Michael Donahue report?
He reports beneficial ownership of 643,850 shares of Mainz Biomed N.V. common stock, which represents 10.7% of that class of securities.
Is Kevin Michael Donahue part of a group in this MYNZ Schedule 13G filing?
No. The filing indicates he is not part of a group and identifies him as an individual reporting person, rather than a group or institution.
What type of reporting person is listed for this MYNZ Schedule 13G?
The filing classifies Kevin Michael Donahue as an individual (IN) reporting person, with U.S. citizenship.
Where is Mainz Biomed N.V. based according to this Schedule 13G?
The issuer, Mainz Biomed N.V., lists its principal executive offices at Robert Koch Strasse 50, Mainz, Germany, 55129.